New eye drug regimen could mean fewer shots for PCV patients
NCT ID NCT07389980
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial is testing a personalized treatment plan using high-dose aflibercept (8 mg) for people with polypoidal choroidal vasculopathy (PCV), a condition that causes vision loss. The goal is to see if adjusting the injection schedule based on each person's response can extend the time between treatments to 8–24 weeks. The study will enroll 50 adults with active PCV and follow them for 96 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- aflibercept 8 mg (a drug injected into the eye to block abnormal blood vessel growth)
- What this could lead to
- If successful, this could allow people with PCV to go longer between eye injections—up to 6 months—while still controlling the disease.
- What could go wrong
- This is a small, early-phase trial with only 50 participants. The personalized dosing schedule may not work for everyone, and there are risks like eye infection or inflammation from the injections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLYPOIDAL CHOROIDAL VASCULOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Yeungnam University Hospital
RECRUITINGDaegu, 42415, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New eye drug could mean fewer shots for PCV patients
- New hope for PCV: higher-dose eye injection may reduce treatment burden
- Eye disease study tracks 5-Year outcomes and recurrence risks
- New combo therapy shows promise for blinding eye condition
- New eye drug trial offers hope for rare vision condition